Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats

Yoshihisa Sugimura, Takashi Murase, Seiji Ishizaki, Kazushige Tachikawa, Hiroshi Arima, Yoshitaka Miura, Ted B. Usdin, Yutaka Oiso

研究成果: Article

25 引用 (Scopus)

抄録

Tuberoinfundibular peptide of 39 residues (TIP39) is a recently discovered neuropeptide identified on the basis of its ability to activate the PTH2 receptor, and it is thought to be the brain PTH2 receptor's endogenous ligand. The PTH2 receptor is highly expressed in the hypothalamus, suggesting a role in the modulation of neuroendocrinological functions. PTHrP, which also belongs to the PTH-related peptides family, stimulates arginine vasopressin (AVP) release. In the present study, therefore, we investigated the effect of centrally administered TIP39 on AVP release in conscious rats. Intracerebroventricular administration of TIP39 (10-500 pmol/rat) significantly suppressed the plasma AVP concentration in dehydrated rats, and the maximum effect was obtained 5 min after administration (dehydration with 100 pmol/rat TIP39, 4.32 ± 1.17 pg/ml; vs. control, 8.21 ± 0.70 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS), 600 mosmol/kg] or hypovolemia [ip injection of polyethylene glycol (PEG)] was also significantly attenuated by an intracerebroventricular injection of TIP39 (HS with 100 pmol/rat TIP39, 2.65 ± 0.52 pg/ml; vs. HS alone, 4.69 ± 0.80 pg/ml; PEG with 100 pmol/rat TIP39, 4.10 ± 0.79 pg/ml; vs. PEG alone, 6.19 ± 0.34 pg/ml). Treatment with naloxone [1.5 mg/rat, sc injection], a nonselective opioid receptor antagonist, significantly reversed the inhibitory effects of TIP39 on AVP release. These results suggest that central TIP39 plays an inhibitory role in the osmoregulation and baroregulation of AVP release and that intrinsic opioid systems are involved in its mechanism.

元の言語English
ページ(範囲)2791-2796
ページ数6
ジャーナルEndocrinology
144
発行部数7
DOI
出版物ステータスPublished - 01-07-2003

Fingerprint

Arginine Vasopressin
Receptor, Parathyroid Hormone, Type 2
Parathyroid Hormone-Related Protein
Injections
Osmoregulation
tuberoinfundibular peptide 39
Hypovolemia
Narcotic Antagonists
Naloxone
Neuropeptides
Dehydration
Opioid Analgesics
Hypothalamus
Ligands
Brain

All Science Journal Classification (ASJC) codes

  • Endocrinology

これを引用

Sugimura, Yoshihisa ; Murase, Takashi ; Ishizaki, Seiji ; Tachikawa, Kazushige ; Arima, Hiroshi ; Miura, Yoshitaka ; Usdin, Ted B. ; Oiso, Yutaka. / Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats. :: Endocrinology. 2003 ; 巻 144, 番号 7. pp. 2791-2796.
@article{0517609ff36c46da9614989e892a4179,
title = "Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats",
abstract = "Tuberoinfundibular peptide of 39 residues (TIP39) is a recently discovered neuropeptide identified on the basis of its ability to activate the PTH2 receptor, and it is thought to be the brain PTH2 receptor's endogenous ligand. The PTH2 receptor is highly expressed in the hypothalamus, suggesting a role in the modulation of neuroendocrinological functions. PTHrP, which also belongs to the PTH-related peptides family, stimulates arginine vasopressin (AVP) release. In the present study, therefore, we investigated the effect of centrally administered TIP39 on AVP release in conscious rats. Intracerebroventricular administration of TIP39 (10-500 pmol/rat) significantly suppressed the plasma AVP concentration in dehydrated rats, and the maximum effect was obtained 5 min after administration (dehydration with 100 pmol/rat TIP39, 4.32 ± 1.17 pg/ml; vs. control, 8.21 ± 0.70 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS), 600 mosmol/kg] or hypovolemia [ip injection of polyethylene glycol (PEG)] was also significantly attenuated by an intracerebroventricular injection of TIP39 (HS with 100 pmol/rat TIP39, 2.65 ± 0.52 pg/ml; vs. HS alone, 4.69 ± 0.80 pg/ml; PEG with 100 pmol/rat TIP39, 4.10 ± 0.79 pg/ml; vs. PEG alone, 6.19 ± 0.34 pg/ml). Treatment with naloxone [1.5 mg/rat, sc injection], a nonselective opioid receptor antagonist, significantly reversed the inhibitory effects of TIP39 on AVP release. These results suggest that central TIP39 plays an inhibitory role in the osmoregulation and baroregulation of AVP release and that intrinsic opioid systems are involved in its mechanism.",
author = "Yoshihisa Sugimura and Takashi Murase and Seiji Ishizaki and Kazushige Tachikawa and Hiroshi Arima and Yoshitaka Miura and Usdin, {Ted B.} and Yutaka Oiso",
year = "2003",
month = "7",
day = "1",
doi = "10.1210/en.2002-0017",
language = "English",
volume = "144",
pages = "2791--2796",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "7",

}

Sugimura, Y, Murase, T, Ishizaki, S, Tachikawa, K, Arima, H, Miura, Y, Usdin, TB & Oiso, Y 2003, 'Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats', Endocrinology, 巻. 144, 番号 7, pp. 2791-2796. https://doi.org/10.1210/en.2002-0017

Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats. / Sugimura, Yoshihisa; Murase, Takashi; Ishizaki, Seiji; Tachikawa, Kazushige; Arima, Hiroshi; Miura, Yoshitaka; Usdin, Ted B.; Oiso, Yutaka.

:: Endocrinology, 巻 144, 番号 7, 01.07.2003, p. 2791-2796.

研究成果: Article

TY - JOUR

T1 - Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats

AU - Sugimura, Yoshihisa

AU - Murase, Takashi

AU - Ishizaki, Seiji

AU - Tachikawa, Kazushige

AU - Arima, Hiroshi

AU - Miura, Yoshitaka

AU - Usdin, Ted B.

AU - Oiso, Yutaka

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Tuberoinfundibular peptide of 39 residues (TIP39) is a recently discovered neuropeptide identified on the basis of its ability to activate the PTH2 receptor, and it is thought to be the brain PTH2 receptor's endogenous ligand. The PTH2 receptor is highly expressed in the hypothalamus, suggesting a role in the modulation of neuroendocrinological functions. PTHrP, which also belongs to the PTH-related peptides family, stimulates arginine vasopressin (AVP) release. In the present study, therefore, we investigated the effect of centrally administered TIP39 on AVP release in conscious rats. Intracerebroventricular administration of TIP39 (10-500 pmol/rat) significantly suppressed the plasma AVP concentration in dehydrated rats, and the maximum effect was obtained 5 min after administration (dehydration with 100 pmol/rat TIP39, 4.32 ± 1.17 pg/ml; vs. control, 8.21 ± 0.70 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS), 600 mosmol/kg] or hypovolemia [ip injection of polyethylene glycol (PEG)] was also significantly attenuated by an intracerebroventricular injection of TIP39 (HS with 100 pmol/rat TIP39, 2.65 ± 0.52 pg/ml; vs. HS alone, 4.69 ± 0.80 pg/ml; PEG with 100 pmol/rat TIP39, 4.10 ± 0.79 pg/ml; vs. PEG alone, 6.19 ± 0.34 pg/ml). Treatment with naloxone [1.5 mg/rat, sc injection], a nonselective opioid receptor antagonist, significantly reversed the inhibitory effects of TIP39 on AVP release. These results suggest that central TIP39 plays an inhibitory role in the osmoregulation and baroregulation of AVP release and that intrinsic opioid systems are involved in its mechanism.

AB - Tuberoinfundibular peptide of 39 residues (TIP39) is a recently discovered neuropeptide identified on the basis of its ability to activate the PTH2 receptor, and it is thought to be the brain PTH2 receptor's endogenous ligand. The PTH2 receptor is highly expressed in the hypothalamus, suggesting a role in the modulation of neuroendocrinological functions. PTHrP, which also belongs to the PTH-related peptides family, stimulates arginine vasopressin (AVP) release. In the present study, therefore, we investigated the effect of centrally administered TIP39 on AVP release in conscious rats. Intracerebroventricular administration of TIP39 (10-500 pmol/rat) significantly suppressed the plasma AVP concentration in dehydrated rats, and the maximum effect was obtained 5 min after administration (dehydration with 100 pmol/rat TIP39, 4.32 ± 1.17 pg/ml; vs. control, 8.21 ± 0.70 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS), 600 mosmol/kg] or hypovolemia [ip injection of polyethylene glycol (PEG)] was also significantly attenuated by an intracerebroventricular injection of TIP39 (HS with 100 pmol/rat TIP39, 2.65 ± 0.52 pg/ml; vs. HS alone, 4.69 ± 0.80 pg/ml; PEG with 100 pmol/rat TIP39, 4.10 ± 0.79 pg/ml; vs. PEG alone, 6.19 ± 0.34 pg/ml). Treatment with naloxone [1.5 mg/rat, sc injection], a nonselective opioid receptor antagonist, significantly reversed the inhibitory effects of TIP39 on AVP release. These results suggest that central TIP39 plays an inhibitory role in the osmoregulation and baroregulation of AVP release and that intrinsic opioid systems are involved in its mechanism.

UR - http://www.scopus.com/inward/record.url?scp=0038336902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038336902&partnerID=8YFLogxK

U2 - 10.1210/en.2002-0017

DO - 10.1210/en.2002-0017

M3 - Article

VL - 144

SP - 2791

EP - 2796

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 7

ER -